Psilocybin clinical trial underway

In 2023, Governor Jay Inslee signed Senate Bill 5263 into law, which mandated a safety study of psilocybin as well as the creation of a regulatory body for the possible recreational and medical use of the drug. Now, the Center for Novel Therapeutics in Addiction Psychiatry’s (NTAP) has started recruitment of a small cohort of veterans and first responders for PsiloStudy, a first-of-its-kind psilocybin clinical trial.
 
Led by Nathan Sackett, MD, MS, PsiloStudy has already learned a lot about the safety and experience of those treated with psilocybin and psychological support. One early challenge has been screening for alcohol use disorder (AUD). Researchers want to identify high-risk participants, however the complexity of AUD and the potential for withdrawal symptoms has made that difficult.
 
The study is continuing to recruit participants. Interested individuals are encouraged to complete the pre-screen questionnaire or reach out to psilostudy@uw.edu with any questions.